Careers  |  Sign In  |  Register  |   Twitter

Researcher Threatens the Future of Incretin Diabetes Drugs

An article in The New York Times reports that the findings of one researcher, Dr. Peter C. Butler, have cast doubt on the safety of diabetes drugs. While studying a new Merck drug, Januvia, Butler “found worrisome changes in the pancreases of the rats that could lead to pancreatic cancer.” Many have criticized the credibility of his findings, as the data have not been replicated by others. But the article explains that the discovery has turned “Dr. Butler into a crusader whose follow-up studies now threaten the future of not only Januvia but all the drugs in its class, which have sales of more than $9 billion annually and are used by hundreds of thousands of people with Type 2 diabetes.”

Read it in The New York Times.